Dr. Reddy's unveils generic BiCNU
The BiCNU brand and generic had a market value of approximately $19.4 million for the most recent 12 months ended August 2021, according to IQVIA.
Dr. Reddy’s is launching carmustine for injection.
The medication is the generic version of Heritage's (doing business as Avet Pharmaceuticals) BiCNU, which is used to treat the symptoms of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphoma.
[Read more: Focus On : How Dr. Reddy's approach sets it apart in a crowded space]
The BiCNU brand and generic had a market value of approximately $19.4 million for the most recent 12 months ended August 2021, according to IQVIA.
Dr. Reddy’s carmustine for injection is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg carmustine and a vial containing 3 mL sterile diluent.
[Read more: Dr. Reddy's intros generic Revlimid in Canada]